Advanced epithelial ovarian cancer: 1993 consensus statements
Darlene Allen(Utrecht University), Elisabeth G.E. de Vries(Karolinska University Hospital), J. Baak(Utrecht University), Neville F. Hacker(New South Wales Department of Health), Leslie Levin(Utrecht University), M Hansen, R F Ozols, PierFranco Conte(University of Padua), G.J.S. Rustin(Unknown), Stuart Kaye(University of Wollongong), D Belpomme(Utrecht University), Hans C. van Houwelingen(Leiden University), T C Hamilton(Utrecht University), Cristiana Sessa(Institute of Oncology Research), Martine Piccart(Université Libre de Bruxelles), M.E.L. van der Burg(Utrecht University), A H Calvert(Utrecht University), W.W. ten Bokkel Huinink, J.P. Neijt(Utrecht University), J. B. Vermorken, J.T. Thigpen(Nova Southeastern University), W. P. Soutter, H.H. Hansen, J Dauplat(Gynecologic Oncology Group), K. Bertelsen(Utrecht University), Birthe Lund(Aalborg University Hospital), C. Tropé, G. Favalli(Utrecht University), J. S. Berek(Utrecht University), E. A. Eisenhauer(Utrecht University)
Cited by 185
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k